Factors of chemoresistant pulmonary tuberculosis progression in patients receiving palliative treatment

Abstract

Objective -to define factors of chemoresistant pulmonary tuberculosis (CRPTB) progression in patients receiving palliative treatment by means of their QL, TNF-α levels and body mass index complex assessment.Materials and methods. 81 CRPTB patients were examined and divided into two groups: the main group consisted of 52 patients receiving palliative treatment and the control group consisted of 29 patients receiving antimycobacterial therapy by category 4 according to drug resistance. The MOS SF-36 questionnaire was used to evaluate the quality of life. Studies of serum TNF-α level were determined by enzyme-linked immunosorbent assay using immunoenzymometric reader Sirio S and a set "Bender MedSystems GmbH" (Austria), (pg/ml). Body mass index was calculated with the help of calculator New BMI (New Body Mass Index), (kg/m 2 ). Results of this study were processed using the modern methods of analysis with the help of a personal computer and the statistical package of the licensed software program Statistica ® for Windows 6.0 (StatSoft Inc., № AXXR712 D833214FAN5).Results. CRPTB patients receiving palliative treatment have simultaneously a high activity of inflammatory specific process, predominant body mass deficit and low quality of life (both its physical and mental component). And along with this in patients receiving CRPTB treatment, activity of specific inflammatory process is 2.2 times lower, normal level of body weight predominate and quality of life is satisfactory (with satisfactory levels of both its components). Assessment of correlation relationships gave an opportunity to find out that in CRPTB patients, receiving palliative treatment, absence of the specific process antimycobacterial therapy leads to an increase in blood serum TNFα which in its turn promotes development of body mass deficit and as a consequence quality of life is decreased through decrease of all its components. In patients receiving etiotropic treatment activity of specific inflammatory process promotes decrease of body mass and quality of life but these changes are not so expressed as in case with patients receiving palliative treatment.Conclusions. Factors of CRPTB progression in patients receiving palliative treatment include increase of TNFα level in the blood serum (≥180 pg/ml), deficit in body mass (≤18.1 kg/m 2 ), decrease in quality of life index (≤50 relative units).Фактори прогресування хіміорезистентного туберкульозу легень у хворих, які перебувають на паліативному лікуванні О. М. Разнатовська, Г. В. Худяков Мета роботи -визначення факторів прогресування хіміорезистентного туберкульозу (ХРТБ) легень у хворих, які перебувають на паліативному лікуванні, шляхом комплексного оцінювання якості життя, а також рівнів TNF-α та індексу маси тіла.Матеріали та методи. Обстежили 81 хворого на ХРТБ легень. Пацієнтів поділили на 2 групи: основна -52 особи, які перебувають на паліативному лікуванні, контрольна -29 осіб, які отримують антимікобактеріальну терапію за категорією 4 відповідно до профілю медикаментозної резистентності. Для оці...

The clinical significance of insulin-like growth factor-1 and cystatin C in predicting the risk of developing complications of chemoresistant pulmonary tuberculosis in patients undergoing palliative treatment

“…in the previous paper [13], pointing out that their levels were significantly worse in pulmonary CRBT patients in PT compared with pulmonary CRTB patients receiving AMBT.…”

Features of pregnancy course in women with chemoresistant tuberculosis (a literature review)

“…As of 2017, there are 558,000 people with rifampicin-resistant tuberculosis (RifTB), which is the most effective first-line drug, registered in the world, and 82 % have multidrug-resistant tuberculosis (MDR-TB). Successful treatment of patients with MDR-TB remains low -55 % and MDR-TB often ends with palliative care [2,3].…”